Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer.
Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S et al, for the DYNAMIC Investigators.
N Engl J Med 2022; 386: 2261-2272.
Patients were randomized to adjuvant chemotherapy depending on the presence of circulating DNA (n=302), or a control group (n=153). Fewer patients in the DNA group had chemotherapy (15 versus 28%), without compromising the rate of recurrence-free survival at a median of 37 months.
Comment: The optimal adjuvant treatment for surgically treated colorectal cancer continues to evolve. This study is another step forwards, and helps limit adjuvant therapy to those who will benefit most.
19 September 2022
Read paperAcademy
Part of the charitable activity of the Society, BJS Academy is an online educational resource for current and future surgeons.
The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.
